OMDA · Omada Health, Inc. · Stock research

TXG

10x Genomics, Inc.

Theme cluster led by SEZL peer name. Stated win-probability p=0.64. Broad breadth (7 peers +30% in 3m) and 1.8x volume participation confirm real theme demand, not a single squeeze.

HNGE

Hinge Health, Inc.

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.

BFLY

Butterfly Network, Inc.

Butterfly Embedded chip-licensing thesis just got marquee validation: Midjourney's up-to-$74M/5yr deal to build a full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18), plus a 2nd Embedded partner (Aleph Neuro brain imaging, 2026-06-25). Re-rated from device-maker to AI-imaging silicon licensor; theme ACCELERATING but shares doubled to ~$8.8 in three weeks into a binary Q2 print, whipsawing 18%/session. Easy leg spent.

ADPT

Adaptive Biotechnologies Corporation

clonoSEQ MRD pure-play emerging: a June 15 plan to separate Immune Medicine sharpens an inflecting (+53% MRD revenue, profitability turning) diagnostics story, but a $300M convertible priced June 17 adds near-term delta-hedging overhang. Theme accelerating, tape near 52-wk highs under the $21–22 sell-side band; no dated catalyst until ~Aug 5 earnings.